0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-74.84%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Mind Medicine Stock Discussion
Benzinga· just
GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life-
-People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD-
-Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
NEWS
MindMed Reports First Quarter 2024 Financial Results and Business Updates
MindMed received Breakthrough Therapy Designation (BTD) from the FDA for MM120 in the treatment of GAD in adults, after positive Phase 2b results showing statistically significant activity through 12 weeks.
The Company has a strong financial position with $252.3 million in cash and cash equivalents as of March 31, 2024, sufficient to fund operations into 2026.
MindMed is on track to begin its ...
bought position at 2.60🧠 said it was going to 17.0+ by end of the year. Its half way 💎
now my $Cybin(CYBN.US)$ and $ATAI Life Sciences(ATAI.US)$ are setting up for take off also. 🚀
Women's Day I hope for flowers 🌺
No comment yet